Literature DB >> 7961898

Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase.

A B Hickman1, I Palmer, A Engelman, R Craigie, P Wingfield.   

Abstract

A deletion derivative of the integrase protein from human immunodeficiency virus type-1 (HIV-1) consisting of the central core domain (amino acids 50-212) has been characterized biophysically and biochemically. This deletion mutant is of particular interest for structural studies as it can carry out the disintegration reaction suggesting the presence of an active site and, under certain conditions, is more soluble than full-length integrase. The circular dichroism and fluorescence of the deletion mutant and the 288-residue full-length integrase were similar, indicating that the core residues maintain similar overall conformations in both proteins. The deletion mutant is approximately 10% more alpha-helical than the full-length protein. Analytical centrifugation demonstrated that both proteins undergo monomer-dimer association although the truncated protein showed slightly less tendency to dimerize; the dissociation constants were 2.5 x 10(-5) M for the full-length protein and 8.0 x 10(-5) M for the truncated protein. The disintegration activity of both proteins was also compared. Although a higher concentration of the truncation mutant was required for optimal activity, the mutant did not have altered pH or Mn2+ requirements relative to the full-length protein. The combined biophysical and enzymatic studies suggest that this truncated form of HIV-1 integrase is likely to be useful for structural studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961898

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Retroviral DNA integration.

Authors:  P Hindmarsh; J Leis
Journal:  Microbiol Mol Biol Rev       Date:  1999-12       Impact factor: 11.056

2.  In vitro targeting of strand transfer by the Ty3 retroelement integrase.

Authors:  Xiaojie Qi; Suzanne Sandmeyer
Journal:  J Biol Chem       Date:  2012-04-04       Impact factor: 5.157

3.  Solution conformation and dynamics of the HIV-1 integrase core domain.

Authors:  Nicholas C Fitzkee; James E Masse; Yang Shen; David R Davies; Ad Bax
Journal:  J Biol Chem       Date:  2010-04-01       Impact factor: 5.157

4.  The GP(Y/F) domain of TF1 integrase multimerizes when present in a fragment, and substitutions in this domain reduce enzymatic activity of the full-length protein.

Authors:  Hirotaka Ebina; Atreyi Ghatak Chatterjee; Robert L Judson; Henry L Levin
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

5.  Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues.

Authors:  T M Jenkins; A B Hickman; F Dyda; R Ghirlando; D R Davies; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

6.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

7.  Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium.

Authors:  Y Goldgur; F Dyda; A B Hickman; T M Jenkins; R Craigie; D R Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Getting IN on Viral RNA Condensation and Virion Maturation.

Authors:  Eric O Freed
Journal:  Cell       Date:  2016-08-25       Impact factor: 41.582

9.  Nonspecific alcoholysis, a novel endonuclease activity of human immunodeficiency virus type 1 and other retroviral integrases.

Authors:  M Katzman; M Sudol
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Structural basis for functional tetramerization of lentiviral integrase.

Authors:  Stephen Hare; Francesca Di Nunzio; Alfred Labeja; Jimin Wang; Alan Engelman; Peter Cherepanov
Journal:  PLoS Pathog       Date:  2009-07-17       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.